Data Readout

BioLineRx's GLIX1 dose-escalation trial in glioma advances toward first human data

The oral TET2 activator has no direct precedent in high-grade glioma, so the first-in-human safety and dose-finding results will be the earliest test of whether the mechanism translates from mice to patients.

By AppliedXLJuly 13, 2026Trial NCT07464925

Executive Summary

A first-in-human trial of an oral molecule built to restore a DNA-repair enzyme's activity in tumors is recruiting patients with a glioma type that has exhausted standard options, and the coming update will show whether the mechanism holds up outside animal models.
The primary goal is tolerability and dose-finding, not tumor response, so the readout will establish whether the drug can be dosed safely in patients before any efficacy signal is expected.
No other program in clinical testing shares this drug's target in this disease, so the result will be read as an early gauge of the underlying biology rather than a comparison against a rival mechanism.
The trial has moved cleanly through its early milestones, opening for recruitment on schedule and holding its enrollment target steady, which keeps the readout on a normal operational track.

The trial

NCT07464925 is a Phase 1 safety and dose-finding study of GLIX1 in adults with recurrent or progressive Grade 3 or Grade 4 glioma who have received up to two prior lines of therapy. The trial targets 30 patients and opened for recruitment on April 20, 2026, moving from Not yet recruiting to Recruiting status on May 1, 2026. Its primary endpoints are maximal tolerated dose or recommended dose and the percentage of participants with treatment-emergent adverse events, a safety-first design typical of a first-in-human study. The first patient was dosed by late April 2026, and BioLineRx confirmed dosing again in a May 27, 2026 disclosure. NCT07464925+1

Probability of Success

Endpoint Met22%

Completes89%

Clinical Significance0%

Regulatory41%

The mechanism

GLIX1 is an oral small molecule designed to reactivate TET2, an enzyme suppressed in many cancers that normally drives DNA demethylation, according to BioLineRx and Hemispherian AS. The companies describe the mechanism as inducing tumor-selective DNA strand breaks by triggering excessive base excision repair once TET2 activity is restored, an approach the abstract presented at the American Society of Clinical Oncology's 2026 Annual Meeting frames as first-in-class. Hemispherian's Chief Scientific Officer, Adam Robertson, said the program targets "the field of the cellular DNA damage response" and that GLIX1 was designed with "a novel mechanism of action designed to induce tumor-selective DNA strand breaks in a broad range of cancers". The preclinical package cited includes antitumor activity in U87-MG and SNB-19 glioblastoma xenograft models and brain-to-plasma drug exposure of 68% to 85% in mice after oral dosing. BioLineRx

The competitive field

No trial in clinical testing shares GLIX1's TET2 target in high-grade glioma or any other indication. The nearest neighbors in this disease are small-molecule programs aimed at different targets, including IDH1 inhibitors safusidenib and olutasidenib, the BRAF inhibitor tovorafenib, and the DRD2-targeting dordaviprone, none of which bear on whether a TET2 activator can achieve tumor-selective DNA damage in glioma. That isolation means the readout carries no comparator to benchmark against; it will instead be judged on its own tolerability and any early activity signal it produces.

Operational status

The trial has recorded two registry events since its March 11, 2026 posting: initial submission and the May 1, 2026 shift to Recruiting, with no protocol amendments to eligibility, endpoints, or enrollment target. Enrollment guidance has held flat at 30 patients, a result the operational risk model characterizes as within the routine band, not a cut or an increase requiring explanation. The primary completion date on record is June 1, 2027, and the sponsor's own disclosures have separately pointed to data from the Phase 1 portion arriving in the first half of 2027, alongside the nearer-term event window covering the second half of 2026. NCT07464925+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.